# US 10,864,187 B2 · Method for treating infectious diseases with isothiocyanate functional compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,864,187 B2
- Document ID: US10864187B2
- Status: Granted
- Kind: B2
- Application number: 16/453,972
- Filed: 2019-06-26
- Published: 2020-03-05
- Granted: 2020-12-15
- Earliest claimed: 2012-07-26
- Assignees: The William M. Yarbrough Foundation
- Applicants: Michael E. Silver
- Inventors: Michael E. Silver
- Web page: https://patentgrep.com/patent/US10864187B2

## CPC

- A61K 31/26: Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 31/16: Amides, e.g. hydroxamic acids
- A61K 31/195: having an amino group
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A method for treating an infectious disease, including the step of administering an isothiocyanate functional surfactant to a patient having an infectious disease. In one embodiment, the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

## Claims

### Claim 1

A method for treating a bacterial infection, comprising the step of:
administering an isothiocyanate functional surfactant to a patient having a bacterial infection, wherein the isothiocyanate functional surfactant is represented by the following chemical structure:
wherein R1 is selected from the group consisting of an alkyl group containing 1 to 25 carbon atom(s); wherein R2 is selected from the group consisting of NCS; and wherein R3-R5 are each independently selected from the group consisting of H; OH; and an alkyl, and alkanoyl group containing 1 to 25 carbon atom(s) with the proviso that at least one of R3-R5 is selected from the group consisting of an alkyl, and alkanoyl, group containing 8 to 25 carbon atoms.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:
wherein X comprises an integer ranging from approximately 1 to approximately 25, and wherein Y comprises an integer ranging from approximately 6 to approximately 25.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

### Claim 4 (depends on 1)

The method according to claim 1, wherein the deprotonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:
wherein R1 is selected from the group consisting of an alkyl group containing 1 to 25 carbon atom(s); wherein R2 is selected from the group consisting of NCS; and wherein R3-R5 are each independently selected from the group consisting of H; OH; and an alkyl, and alkanoyl group containing 1 to 25 carbon atom(s) with the proviso that at least one of R3-R5 is selected from the group consisting of an alkyl, and alkanoyl, group containing 8 to 25 carbon atoms; and wherein X comprises a counter cation.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the patient is a mammal.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the mammal is a human.

### Claim 7

A method for treating a viral infection, comprising the step of:
administering an isothiocyanate functional surfactant to a patient having a viral infection, wherein the isothiocyanate functional surfactant is represented by the following chemical structure:
wherein R1 is selected from the group consisting of an alkyl group containing 1 to 25 carbon atom(s); wherein R2 is selected from the group consisting of NCS; and wherein R3-R5 are each independently selected from the group consisting of H; OH; and an alkyl, and alkanoyl group containing 1 to 25 carbon atom(s) with the proviso that at least one of R3-R5 is selected from the group consisting of an alkyl, and alkanoyl, group containing 8 to 25 carbon atoms.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:
wherein X comprises an integer ranging from approximately 1 to approximately 25, and wherein Y comprises an integer ranging from approximately 6 to approximately 25.

### Claim 9 (depends on 7)

The method according to claim 7, wherein the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

### Claim 10 (depends on 7)

The method according to claim 7, wherein the deprotonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:
wherein R1 is selected from the group consisting of an alkyl group containing 1 to 25 carbon atom(s); wherein R2 is selected from the group consisting of NCS; and wherein R3-R5 are each independently selected from the group consisting of H; OH; and an alkyl, and alkanoyl group containing 1 to 25 carbon atom(s) with the proviso that at least one of R3-R5 is selected from the group consisting of an alkyl, and alkanoyl, group containing 8 to 25 carbon atoms; and wherein X comprises a counter cation.

### Claim 11 (depends on 7)

The method according to claim 7, wherein the patient is a mammal.

### Claim 12 (depends on 7)

The method according to claim 7, wherein the mammal is a human.

### Claim 13

A method for treating a fungal infection, comprising the step of:
administering an isothiocyanate functional surfactant to a patient having a fungal infection, wherein the isothiocyanate functional surfactant is represented by the following chemical structure:
wherein R1 is selected from the group consisting of an alkyl group containing 1 to 25 carbon atom(s); wherein R2 is selected from the group consisting of NCS; and wherein R3-R5 are each independently selected from the group consisting of H; OH; and an alkyl, and alkanoyl group containing 1 to 25 carbon atom(s) with the proviso that at least one of R3-R5 is selected from the group consisting of an alkyl, and alkanoyl, group containing 8 to 25 carbon atoms.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:
wherein X comprises an integer ranging from approximately 1 to approximately 25, and wherein Y comprises an integer ranging from approximately 6 to approximately 25.

### Claim 15 (depends on 13)

The method according to claim 13, wherein the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

### Claim 16 (depends on 13)

The method according to claim 13, wherein the deprotonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:
wherein R1 is selected from the group consisting of an alkyl group containing 1 to 25 carbon atom(s); wherein R2 is selected from the group consisting of NCS; and wherein R3-R5 are each independently selected from the group consisting of H; OH; and an alkyl, and alkanoyl group containing 1 to 25 carbon atom(s) with the proviso that at least one of R3-R5 is selected from the group consisting of an alkyl, and alkanoyl, group containing 8 to 25 carbon atoms; and wherein X comprises a counter cation.

### Claim 17 (depends on 13)

The method according to claim 13, wherein the patient is a mammal.

### Claim 18 (depends on 13)

The method according to claim 13, wherein the mammal is a human.